Ask AI
Back Back
ET and PV Call to Action
A Call to Action: Enhancing Diagnostic Clarity and Treatment Navigation in Essential Thrombocythemia and Polycythemia Vera

Released: January 27, 2026

Andrew Kuykendall
Andrew Kuykendall, MD
Activity Information

Activity

Continue to Activity
Key Takeaways
  • Prioritize accurate diagnosis of ET and PV using a structured approach that includes appropriate molecular testing and use of bone marrow biopsy.
  • Ground treatment decisions in thrombotic risk and symptom burden, emphasizing clarity about benefits and risks.
  • Plan proactively for therapy transitions after hydroxyurea or interferon, with individualized choices that reflect patient needs and emerging therapeutic options.

Essential thrombocythemia (ET) and polycythemia vera (PV) represent chronic myeloproliferative neoplasms that require thoughtful, individualized care. Although uncommon, these conditions may be found with incidental findings of abnormal blood counts or in the aftermath of a thrombotic event and carry lifelong implications for patients—from thrombotic risk to symptom burden and disease transformation to myelofibrosis or acute myeloid leukemia with treatment sequencing decisions that may evolve over decades. As the therapeutic landscape expands and diagnostic expectations become more refined, healthcare professionals (HCPs) across care settings have an opportunity to evaluate their approach, ensuring clarity, consistency, and confidence for both patients and healthcare teams.

Refining Diagnostic Confidence: A Structured, Patient‑Centered Approach
When approaching elevated platelet counts or elevated red blood cell count, hemoglobin, or hematocrit, HCPs often face a wide differential. Secondary causes such as inflammatory conditions, chronic cardiopulmonary disease, or specific drug exposure remain important to consider when confirming or excluding a diagnosis of ET or PV. To this end, a brief but intentional review of patient history, medication exposures, comorbidities, and laboratory markers helps to determine whether alternative explanations are likely. This step avoids unnecessary testing and positions molecular and marrow evaluations to provide the most meaningful information.

Once ET or PV is suspected, mutation testing, including assessment for JAK2, CALR, and MPL, forms the cornerstone of diagnostic evaluation. Virtually all patients with PV carry a JAK2 mutation, whereas patients with ET display a more heterogeneous distribution of mutations across JAK2 (approximately 60%), CALR (approximately 25%), and MPL (approximately 5%-7%). Identifying the molecular driver supports not only diagnostic clarity but also more informed conversations with patients about prognosis and thrombotic risk.

Beyond molecular testing, bone marrow biopsy remains a fundamental tool in the diagnosis and management of patients with ET or PV. The role of bone marrow biopsy is particularly important when distinguishing ET from prefibrotic myelofibrosis, identifying baseline marrow fibrosis, or clarifying an atypical presentation. At the same time, HCPs may encounter scenarios where biopsy is unlikely to alter immediate therapeutic decisions, for example, in individuals with well‑supported clinical and laboratory features of PV or in those for whom procedural risks outweigh anticipated benefits. Applying bone marrow biopsy in a manner tailored to the clinical context helps to balance diagnostic thoroughness with practical considerations, including patient comfort.

Ultimately, a structured and transparent diagnostic process can help HCPs navigate the inherent nuances of ET and PV evaluation while providing patients with a clear understanding of why each step is recommended.

Risk Assessment: Emphasizing Factors That Matter Most
In daily practice, thrombotic risk remains the central consideration guiding management decisions in ET and PV. Age, history of thrombosis, and the presence of a JAK2 mutation are the strongest and most consistent risk determinants observed across clinical experience. These elements provide a durable foundation for risk discussions and can help HCPs and patients align on treatment priorities. Various alternative prognostic scoring systems incorporating additional molecular features are available for risk assessment in ET and PV, but the clinical utility of these risk assessments remains an area of ongoing debate and evolution.

Laboratory values such as platelet count, white blood cell count, and hematocrit also influence management, but their interpretation often benefits from nuance and context. Patients, understandably, may assume that count normalization is the primary indicator of treatment success. Discussing the broader therapeutic goals—reduced risk of thrombotic events, improvement in symptom burden, and maintenance of quality of life—helps set expectations and minimize confusion when dose adjustments result in modest fluctuations in blood counts. Individual symptom profiles further shape therapeutic conversations. Some patients with PV, for example, may experience symptomatic relief with hematocrit targets slightly lower than the traditional threshold; others may prioritize minimizing medication exposures and prefer a more conservative approach. Similarly, patients with ET may weigh the discomfort of microvascular symptoms against the potential trade‑offs of cytoreductive therapy. By integrating risk factors with patient‑specific concerns, HCPs can develop plans that feel both evidence informed and personally meaningful.

Navigating Therapy Beyond Hydroxyurea: Aligning Options With Patient Goals
Hydroxyurea has long served as an initial cytoreductive therapy for many patients with ET and PV. Over time, however, some patients may experience diminished benefit, adverse effects, or disease evolution, prompting reconsideration of their regimen. Planning for these potential transitions early and revisiting expectations regularly can make later decisions more straightforward. Interferon formulations also provide a reasonable initial treatment option and are a favored choice for younger patients.

In PV, the presence of splenomegaly, progressive symptoms, difficulty maintaining hematocrit goals, or intolerance to hydroxyurea often prompt consideration of alternative therapies. Ruxolitinib is frequently used in these settings, particularly when symptom control or spleen reduction becomes a priority. Interferon formulations, including pegylated and ropegylated options, are increasingly used given their potential to reduce the number of blood cells that harbor the JAK2 mutation, potentially affecting disease progression. Each therapy carries unique considerations related to adverse effect profiles, administration schedules, and monitoring needs, underscoring the value of individualized discussion.

In ET, choosing a second‑line therapy is more variable and depends not only on thrombotic risk but also on bleeding risk, symptom patterns, comorbidities, and personal preferences. Interferon-based therapies, anagrelide, and JAK pathway inhibitors each have a role for select patients. Because evidence remains limited in certain second‑line scenarios, engaging patients in clear, collaborative dialogue remains especially important.

Across both conditions, collaboration with experts in ET and PV and aligning therapeutic decisions with patient priorities—maintaining flexibility as needs evolve—strengthens the overall care experience.

Preparing for Emerging Therapies: Building Familiarity With What Is Ahead
The treatment landscape for ET and PV is expanding in thoughtful and potentially meaningful ways. Several investigational agents are in advanced development, including therapies targeting epigenetic regulators (eg, bomedemstat, givinostat, pelabresib), hepcidin pathways (eg, rusfertide), and specific molecular drivers such as mutant CALR (eg, INCA033989). As these therapies continue to move through clinical development, they may offer new potentially disease-modifying options for patients who have previously exhausted standard treatments.

Keeping pace with emerging data can be challenging in busy clinical environments. However, even brief periodic updates can help HCPs build familiarity with new mechanisms of action, potential benefits, and anticipated roles of novel therapies in future treatment algorithms. This awareness not only prepares HCPs for upcoming changes but also empowers them to guide patients who may arrive already informed about investigational developments.

Strengthening Communication and Continuity Through Shared Decision‑making
Shared decision‑making plays a central role in supporting patients through the long‑term management of ET and PV. Because patients often experience prolonged periods of surveillance punctuated by occasional treatment transitions, consistent and clear communication helps to maintain trust and decreases anxiety. Early in the relationship, a broad yet accessible overview of disease mechanisms, risks, and treatment goals can provide a stable framework that supports future decisions.

Patients may differ widely in how much detail they prefer. Understanding these preferences and tailoring communication accordingly promotes engagement and fosters therapeutic rapport. The care journey is strengthened even further when pharmacists, advanced practice providers, nurses, and support staff work in close collaboration. These team members often address adverse effects, medication questions, adherence challenges, and psychosocial concerns, reinforcing shared goals and ensuring continuity across visits.

Looking Forward
Care for patients with ET and PV continues to evolve through a combination of long‑standing principles and emerging opportunities. By maintaining clear diagnostic pathways, applying molecular and marrow assessments thoughtfully, focusing risk discussions on meaningful drivers, and developing proactive treatment plans that extend beyond hydroxyurea, HCPs can offer care that is consistent, adaptable, and centered on the patient experience. As new therapies advance, maintaining awareness of their potential roles will help to ensure that treatment decisions remain aligned with both current evidence and individual patient priorities.

Your Thoughts
What are your current challenges in the management of patients with ET or PV? What topic would you like experts to elaborate on in our ongoing educational program on ET and PV? Please answer the polling question and be sure to visit the program page to access various educational activities including podcasts, text modules, and slides on the care of patients with ET and PV.

Continue to Activity

Poll

1.

Which of the following topics in the care of patients with ET or PV would you like more education about?

Submit